Project Details
Description
A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia (H
| Status | Active |
|---|---|
| Effective start/end date | 11/21/23 → 11/30/33 |
Funding
- ALEXION PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.